BCIQ Profiles

Company Profile Report

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy
Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56% incidence of acute kidney injury in PRISM-MDR's active treatment arm, higher than the expected

Read the full 484 word article

How to gain access

Continue reading with a
two-week free trial.